Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 82 people enrolled
- Started
- 12 Aug 2020
- Ended
- 19 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Apixaban 2.5 MG Oral Tablet
- Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Record updated
- 22 June 2025
Who can take part
- Age
- 18 years to 89 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adult (>18 years) women
- Scheduled to undergo unilateral or bilateral microsurgical breast reconstruction with free abdominal flaps (i.e. muscle-sparing transverse rectus abdominis musculocutaneous [TRAM] and/or deep inferior epigastric artery perforator [DIEP]) flap)
- Caprini score of 6 or greater
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Active bleeding
- History of bleeding disorder
- History of coagulopathy
- History of heparin-induced thrombocytopenia
- History of liver disease
- Uncontrolled hypertension
- History of alcohol and/or substance abuse
- History of renal disease (creatinine clearance <30 mL/min; serum creatinine >1.6 mg/dL)
- Contraindication to the use of apixaban or enoxaparin
- Major neurosurgical intervention (brain/spine) within the past 90 days
- Ophthalmologic procedure within the past 90 days
- Need for therapeutic anticoagulation
- Pregnant or Nursing
Where in United States
- Stanford University Medical CenterStanford, United States
About the trial
What the trial wants to find out
Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite guideline-compliant prophylaxis. A population at particular risk is the growing number of patients who undergo autologous breast reconstruction. Direct oral anticoagulants (DOAC) might be a less invasive, yet, more efficacious mode of chemoprophylaxis in this patient population. Hence, the proposed work has the potential to cause a paradigm shift in chemoprophylaxis guidelines in a large population of patients undergoing plastic surgery.
The 2 groups in the trial
- ApixabanTreatment being tested
Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.
Treatment: Apixaban 2.5 MG Oral Tablet
- EnoxaparinExisting treatment, for comparison
Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.
Treatment: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial Comparing Apixaban Versus Enoxaparin Following Microsurgical Breast Reconstruction
- Record updated
- 22 June 2025